Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Aim(s): We investigated the value of pre-therapy 68Ga-DOTATATE PET and serum Chromogranin A (ChgA) in predicting short-term progression free survival (PFS).
Materials and methods: We retrospectively reviewed 57 patients (62.4 ± 11.2 years) who received at least one dose of 177Lu-DOTATATE between Dec. 2016 and May 2019 at our institution. 45 patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) had a pre-therapy 68Ga-DOTATATE PET/CT or PET/MR. Pre-therapy serum ChgA level was available in 36 patients. Quantitative image analysis of 68Ga-DOTATATE PET was performed using MIM software. Extrahepatic and total 68Ga-DOTATATE avid tumor volumes (DATV) were measured and dichotomized into larger and smaller groups (130 and 1000 ml as threshold respectively). ChgA was dichotomized into higher and lower groups using 10000 ng/mL as the threshold. Kaplan-Meier survival analysis was performed.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.